selected scholarly activity
-
academic article
- Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. European Journal of Cancer. 135:203-210. 2020
- Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. Eur Urol Oncol. 3:372-381. 2020
- Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic. Journal of the Canadian Urological Association. 14:E154-E158. 2020
- A A Canadian consensus forum on the management of patients with advanced prostate cancer. Journal of the Canadian Urological Association. 14:E137-E149. 2020
- Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. Journal of the Canadian Urological Association. 14:122-129. 2020
- Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd BCC-CUA-CUOG bladder cancer quality of care consensus meeting. Journal of the Canadian Urological Association. 14:E115-E125. 2020
- Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. JCO Glob Oncol. 6:293-306. 2020
- From Famine to Feast: Treating Urinary Malignancies in the Immunotherapy Era. European Urology Focus. 6:1-2. 2020
- State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. European Urology Focus. 6:37-40. 2020
- Capturing recurrence in urothelial carcinoma: “more than meets the eye”. Translational Andrology and Urology. 8:S524-S527. 2019
- Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications. 10:4346. 2019
- Response of Primary Renal Cell Carcinoma to Systemic Therapy. European Urology. 76:852-860. 2019
- Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Journal of the Canadian Urological Association. 13:343-54. 2019
- Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. Journal of the Canadian Urological Association. 13:166-174. 2019
- Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. Eur Urol Oncol. 2019
- Systemic treatments for metastatic urothelial carcinoma. Expert Opinion on Pharmacotherapy. 20:201-208. 2019
- Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. European Urology. 75:100-110. 2019
- Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 6:5. 2018
- Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British Journal of Cancer. 119:707-712. 2018
- The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma. Cancer immunology research. 6:758-765. 2018
- Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). British Journal of Cancer. 118:1434-1441. 2018
- Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. British Journal of Cancer. 118:1238-1242. 2018
- Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. Cancer immunology research. 6:402-408. 2018
- Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Kidney Cancer. 2:31-36. 2018
- JAVELIN: avelumab another spear to fight urothelial carcinoma. The Lancet Oncology. 19:5-7. 2018
- Pan-urologic cancer genomic subtypes that transcend tissue of origin. Nature Communications. 8:199. 2017
- Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 15:724-732. 2017
- Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. Journal for ImmunoTherapy of Cancer. 5:66. 2017
- Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non–Lymph Node Distant Metastasis. Clinical Genitourinary Cancer. 15:e1089-e1094. 2017
- Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget. 8:103428-103436. 2017
- Immunotherapy in the Elderly. European Urology Focus. 3:403-412. 2017
- First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. Journal of the Canadian Urological Association. 11:112-112. 2017
- Manifestations of Von Hippel Lindau syndrome: a retrospective national review. QJM - Monthly Journal of the Association of Physicians. 107:291-296. 2014
-
conference paper
- Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 2020
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). Journal of Clinical Oncology. 2020
- Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis). Journal of Clinical Oncology. 2020
- Real-world utilization and safety of ipilimumab plus nivolumab (I plus N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis). Journal of Clinical Oncology. 2020
- Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Journal of Clinical Oncology. 2020
- CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 885-885. 2019
- Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC). Annals of Oncology. 396-396. 2019
- Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology. 4516-4516. 2019
- Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology. 568-568. 2019
- Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 566-566. 2019
- Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC). Annals of Oncology. viii311-viii311. 2018
- Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. Journal of Clinical Oncology. e16065-e16065. 2017
- Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology. e16078-e16078. 2017
- Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience. Annals of Oncology. vi285-vi285. 2016
- Optimizing the travel experiences of children and families during flight.. Journal of Investigative Medicine. S173-S173. 2006